New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
A common heart drug has shown promise to delay the onset of Huntington's disease -- a progressive and inherited brain ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...